Momenta Pharmaceuticals Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Momenta Pharmaceuticals Inc (MNTA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Momenta Pharmaceuticals Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 30M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-12.1% annualized vs trailing 12 months).
- Peer revenue share: Momenta Pharmaceuticals Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
MNTA Sales vs. its Competitors, Q2 2020
Momenta Pharmaceuticals Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
API endpoints for this dataset
For context: the Biotechnology & Pharmaceuticals industry grew revenue 21.4% year over year, combined, vs 27.6% for Momenta Pharmaceuticals Inc. Momenta Pharmaceuticals Inc's share of combined industry revenue moved from 0.01% to 0.01%, a gain of 0.00 percentage points.
Momenta Pharmaceuticals Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Momenta Pharmaceuticals inc | - | No | No | No |
| High-Confidence Competitors (133) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MNTA Stock Performance relative to its Competitors
MNTA Stock Performance relative to High-Confidence Competitors
Momenta Pharmaceuticals Inc's Competitors Named by the Company
Competitive relationships identified from Momenta Pharmaceuticals Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Medtronic plc | Company report | 85% |
| Boston Scientific Corporation | Company report | 85% |
| Angiodynamics Inc | Company report | 85% |
| Intuitive Surgical Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Encision Inc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| United Health Products Inc | Company report | 85% |
| Co diagnostics Inc | Company report | 85% |
| Catheter Precision Inc | Company report | 85% |
| Integra Lifesciences Holdings Corp | Company report | 85% |
| Globus Medical Inc | Company report | 85% |
| Bioventus Inc | Company report | 85% |
| Koninklijke Philips Nv | Company report | 85% |
| Acutus Medical Inc | Company report | 85% |
| Novavax inc | Company report | 85% |
| Cardiovascular Systems, Inc. | Company report | 85% |
| Inspiremd Inc | Company report | 85% |
| Briacell Therapeutics Corp | Company report | 85% |
| Acumen Pharmaceuticals Inc | Company report | 85% |
| Stryker Corp | Company report | 85% |
| Voyager Therapeutics Inc | Company report | 85% |
| Enovis Corp | Company report | 85% |
| Biodexa Pharmaceuticals Plc | Company report | 85% |
| Black Diamond Therapeutics Inc | Company report | 85% |
| Monogram technologies inc | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Vanda Pharmaceuticals Inc | Company report | 85% |
| Paragon 28 inc | Company report | 85% |
| Addex Therapeutics Ltd | Company report | 85% |
| Mersana Therapeutics inc | Company report | 85% |
| Sutro Biopharma Inc | Company report | 85% |
| Apexigen Inc | Company report | 85% |
| Morphic Holding inc | Company report | 85% |
| Sellas Life Sciences Group Inc | Company report | 85% |
| Agentix Corp | Company report | 85% |
| Tempest Therapeutics Inc | Company report | 85% |
| Oragenics Inc | Company report | 85% |
| Curanex Pharmaceuticals Inc | Company report | 85% |
| Ss Innovations International Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Momenta Pharmaceuticals Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from Momenta Pharmaceuticals Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.
